Filing Flows › Korsana Biosciences (KRSA) › Q4 2024
Korsana Biosciences (KRSA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 4, 2025
Korsana Biosciences (KRSA) reported revenue of $1.8M for the fourth quarter 2024 (Q4 2024) and +831% from the quarter before. Operating margin was 27.8%, net earnings $530K (29.3% of revenue).
Korsana Biosciences, Q4 2024: revenue $1.8M, operating margin 27.8%, net earnings $530K, operating cash flow $360K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.8M | +831% | — |
| Operating profit | $502K | — | — |
| Net earnings | $530K | — | — |
| Operating cash flow | $360K | — | — |
What changed
Revenue was $1.8M in Q4 2024, up 831% from the previous quarter.
Operating profit was $502K, a 27.8% margin. Net earnings were $530K. The effective tax rate was 0.0%.
Operating cash flow was $360K, 68% of net earnings. Non-cash charges added back $122K of share-based compensation. Working capital and other items used $292K.
Questions
What was Korsana Biosciences' revenue in the fourth quarter 2024?
Korsana Biosciences (KRSA) reported revenue of $1.8M for the fourth quarter 2024 (Q4 2024) and +831% from the quarter before.
Was Korsana Biosciences profitable in the fourth quarter 2024?
Operating profit was $502K (27.8% of revenue) and net earnings $530K.